Compare BBAR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | LQDA |
|---|---|---|
| Founded | 1886 | 2004 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 1997 | 2020 |
| Metric | BBAR | LQDA |
|---|---|---|
| Price | $16.81 | $37.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $17.00 | ★ $41.00 |
| AVG Volume (30 Days) | 586.3K | ★ 1.1M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $18.32 | $278.87 |
| Revenue Next Year | $11.04 | $57.13 |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $7.76 | $11.85 |
| 52 Week High | $23.10 | $46.67 |
| Indicator | BBAR | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 61.12 | 49.78 |
| Support Level | $16.71 | $31.75 |
| Resistance Level | $17.14 | $39.19 |
| Average True Range (ATR) | 0.76 | 2.12 |
| MACD | 0.14 | 0.09 |
| Stochastic Oscillator | 94.95 | 37.52 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.